Effects of immediate or delayed addition of platelet additive solution on the in vitro quality of apheresis platelets

BACKGROUND: There is little knowledge how different hold times of hyperconcentrated platelet (PLT) suspensions (HPSs) before the addition of platelet additive solution (PAS) might affect PLT quality. We compared the in vitro quality of single‐donor PLT concentrates (SDPs) with immediate or delayed PAS addition and studied the quality of collected concurrent plasma (CP).

[1]  S. Wagner,et al.  In vitro variables of apheresis platelets are stably maintained for 7 days with 5% residual plasma in a glucose and bicarbonate salt solution, PAS‐5 , 2012, Transfusion.

[2]  Lily Lin,et al.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM , 2011, Transfusion Medicine and Hemotherapy.

[3]  P. Mintz,et al.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology , 2010, Transfusion.

[4]  C. Homma,et al.  Comparison between in vitro qualities of platelets washed with commercially available additive solutions and those washed with M‐sol , 2010, Vox sanguinis.

[5]  J. Ringwald,et al.  Do platelets stored in additive solution really show limited osmotic balance? , 2009, Transfusion.

[6]  S. Tien,et al.  Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation – a single centre experience , 2009, Vox sanguinis.

[7]  C. Chapman,et al.  How much residual plasma may cause TRALI? , 2008, Transfusion medicine.

[8]  J. Hirayama,et al.  Maintenance of platelet in vitro properties during 7‐day storage in M‐sol with a 30‐hour interruption of agitation , 2008, Transfusion.

[9]  Joyce Curvers,et al.  Flow cytometric measurement of CD62P (P‐selectin) expression on platelets: a multicenter optimization and standardization effort , 2008, Transfusion.

[10]  C. Homma,et al.  Storage of platelets in 30 percent plasma and 70 percent M‐sol additive solution , 2008, Transfusion.

[11]  C. Homma,et al.  Storage of platelets in a novel additive solution (M‐sol), which is prepared by mixing solutions approved for clinical use that are not especially for platelet storage , 2007, Transfusion.

[12]  R. Zimmermann,et al.  Impact of different hold time before addition of platelet additive solution on the in vitro quality of apheresis platelets , 2006, Transfusion.

[13]  J. Ringwald,et al.  The New Generation of Platelet Additive Solution for Storage at 22°C: Development and Current Experience , 2006 .

[14]  J. Ringwald,et al.  Collection of hyperconcentrated platelets with Trima Accel , 2006, Vox sanguinis.

[15]  R. Zimmermann,et al.  Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality , 2005, Vox sanguinis.

[16]  R. Goodrich,et al.  Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light , 2004, Transfusion.

[17]  I. Romon,et al.  Implementation of a strategy to prevent TRALI in a regional blood centre , 2004, Transfusion medicine.

[18]  R. Zimmermann,et al.  Preparation of FFP as a by‐product of plateletpheresis , 2002, Transfusion.

[19]  J. Wiltfang,et al.  Different preparation methods to obtain platelet components as a source of growth factors for local application , 2001, Transfusion.

[20]  M. A. Mansoor,et al.  Endogenous glutathione and platelet function in platelet concentrates stored in plasma or platelet additive solution , 2001, Transfusion medicine.

[21]  Napier.  Guide to the Preparation, Use and Quality Assurance of Blood Components. , 1998 .

[22]  R. Zimmermann,et al.  Evaluation of a Platelet Apheresis Technique for the Preparation of Leukocyte-Reduced Platelet Concentrates , 1998, Vox Sanguinis.

[23]  S. Murphy,et al.  A multi‐laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion , 1998, Transfusion.

[24]  R. Zimmermann,et al.  Comparison of COBE white cell‐reduction and standard plateletpheresis protocols in the same donors , 1997, Transfusion.

[25]  J. Loscalzo,et al.  In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Moroff,et al.  Validation of use of the Nageotte hemocytometer to count low levels of white cells in white cell‐reduced platelet components , 1994, Transfusion.

[27]  W H Dzik,et al.  Large‐volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC‐reduced platelets: validation and application for quality control of WBC‐reduced platelets prepared by apheresis and filtration , 1993, Transfusion.

[28]  J. Ringwald,et al.  The new generation of platelet additive solution for storage at 22 degrees C: development and current experience. , 2006, Transfusion medicine reviews.

[29]  L. Dumont,et al.  Platelet surface P-selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). , 1999, Transfusion medicine reviews.